Dendritic cells (DC), the most potent 'professional' antigenpresenting cells, hold promise for improving the immunotherapy of cancer. In this study, we investigated the ability of normal donor DC pulsed ex vivo with 12 mer bcr-abl (b3a2) peptide to generate b3a2-specific autologous or HLA-identical sibling donor's cytotoxic T-lymphocytes (CTL). DC that were grown from normal peripheral blood adherent cells or purified DC precursors in the presence of GM-CSF and IL-4, were pulsed with b3a2-peptide then were induced to become mature and functional cells by the addition of TNF-␣. These peptide-pulsed mature DC elicited a potent b3a2-specific CTL response in vitro. The b3a2-peptide pulsed DC-primed peripheral blood lymphocytes (PBL) displayed significantly higher cytotoxic activity compared with peptide non-pulsed DC-primed PBL against target cells, which are b3a2 positive marrow cells derived from HLA-identical sibling chronic myelogenous leukemia (CML) patient, or peptide-pulsed autologous macrophages (P Ͻ 0.001). In addition, the b3a2 peptide-pulsed DC-primed and non-pulsed DC-primed PBL showed no cytotoxic response against peptide non-pulsed autologous macrophages. These findings revealed that normal donor PBL pre-immunized with b3a2-peptide pulsed autologous DC could increase the graftversus-leukemia effect without exaggerating graft-versus-hostdisease. Both CD8 ؉ and CD4 ؉ T lymphocytes were shown to be involved in the effector cell populations. The b3a2 peptidepulsed DC-primed T cells were significantly superior in their production of GM-CSF and TNF-␣ compared with peptide nonpulsed DC-primed T cells. These intriguing preclinical results imply the feasibility of developing b3a2 peptide-DC based protocol for in vitro sensitization of normal donor leukocytes before donor leukocyte transfusions for patients with CML, who relapsed after HLA-matched sibling bone marrow transplantation.
Introduction
Treatment of relapsed chronic myeloid leukemia (CML), after HLA-matched sibling bone marrow transplantation (BMT), with donor leukocyte transfusions (DLT) has proven to have antileukemic effects.
1,2 Nonetheless, this therapy, which is thought to reflect a graft-versus-leukemia (GVL) response against minor histocompatibility antigens on the leukemic clone or against leukemia-specific antigens, 3 is not fully effective for many patients who received DLT. A more specific form of leukemia immunotherapy, which increases the GVL while avoiding graft-versus-host disease would be highly desirable. Utilizing the immune system specifically to target and to eliminate neoplastic cells on the basis of their expression of tumor specific antigens has recently emerged as a promising new approach in cancer immunotherapy. 4 For tumor peptide-based immunotherapies to be successful, it is likely that naive anti-tumor cytotoxic T-lymphocytes (CTL) will need to be primed by 'professional' antigen-presenting cells (APC). 5 Dendritic cells (DC) are known as professional APC and have an exceptional ability to present tumor antigens to naive CTL both in vivo and in vitro. 6, 7 Therefore, immunization with DC preloaded with tumor specific peptides may represent a particularly appealing approach in developing novel cancer vaccines and therapies. 6 In CML, the classical 9;22 translocation results in a bcr-abl fusion gene, which encodes chimeric bcr-abl fusion 210 kDa oncoproteins (p210 bcr-abl ). [8] [9] [10] The two main p210 bcr-abl fusion variants in CML, b2a2 and b3a2 are examples of well characterized antigens expressed by leukemic cells. 11 It has been demonstrated that vaccination with autologous DC prepulsed with tumor specific peptides could stimulate antitumor immunity in patients with B cell lymphoma, 4 prostate cancer, 12 multiple myeloma, 13 and melanoma. 14 Encouraging in vitro results using DC derived from CML patients to induce antileukemic effects were reported as well. [15] [16] [17] It has been reported that CD4
+ T cells recognize bcr-abl peptides, 16, 18, 19 and that CD4
+ class II-restricted T cells are important effectors in antitumor immunity. 20 Besides, bcr-abl junction peptides were reported to induce expansion of bcr-abl specific CD8 + CTL. 21, 22 In order to support the utility of autologous DC in future clinical immunotherapeutic trials, we examined the ability of normal donor peripheral blood lymphocytes (PBL) stimulated with b3a2 peptide loaded autologous DC, to lyse b3a2 positive marrow cells derived from a HLA-identical sibling CML patient, or to lyse autologous macrophages pulsed with b3a2 peptide. In the studies described here, we show that CTL specific for bcr-abl fusion peptide can be generated from normal peripheral blood. These CTL had direct cytotoxic activity against b3a2 positive marrow cells derived from a HLA-identical sibling CML patient who relapsed post-allogeneic BMT, or against b3a2 pulsed autologous macrophages, but not against peptide non-pulsed autologous target cells. The specific cytotoxic activity of b3a2 peptide-pulsed DC-primed PBL was significantly higher than b3a2 peptide non-pulsed DC-primed PBL against the leukemic cells derived from a HLA-identical sibling CML patient, or against the peptide-pulsed autologous macrophages. Besides, b3a2 peptide-pulsed DC-primed T cells were significantly superior in the production of GM-CSF and TNF-␣ compared with peptide non-pulsed DC-primed T cells. In vitro generated DC can be effectively used as APC for the ex vivo expansion of peptide-specific antileukemic CTL. In addition, this vaccine strategy might be applied for DLT in relapsed CML patients after HLA-matched sibling BMT.
Materials and methods

Culture medium
We used complete medium (CM) consisting of RPMI-1640 (Gibco, Grand Island, NY, USA) supplemented with 200 mm l-glutamine, 100 U/ml penicillin G, 100 g/ml streptomycin (Biowhittaker, Walkersville, MD, USA), and 10% heatinactivated autologous plasma.
Recombinant human cytokines
The recombinant human cytokines used were as follows: 100 ng/ml GM-CSF (Kirin Brewery, Maebashi, Japan), 10 ng/ml IL-4 (Genzyme, Cambridge, MA, USA), 10 ng/ml TNF-␣ (Genzyme), and 50 ng/ml M-CSF (Green Cross, Osaka, Japan).
Blood donor, PBMC preparation and CML cells
Blood was collected from four normal volunteer donors after obtaining appropriate informed consents, into preservativefree heparin or, in some experiments into 10% acid citrate dextrose (Sanko Junyaku, Tokyo, Japan) to isolate autologous plasma. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by density-gradient centrifugation (density = 1.077 g/ml, Lymphoprep; Nycomed, Oslo, Norway). The HLA types of the four healthy donors are as follows: donor D1: HLA-A2,24, B48,70, HLA-DR4, HLA-DRB1*0403,0405, HLA-DQ3,4; donor D2: HLA-A11,13,  B51,41, CW6, HLA-DR4,4; donor D3: HLA-A2,28, B38,44,  CW7, HLA-DR13, HLA-DRB1*1301 (or 1316),1303, HLA-DQ1,7; and donor D4: HLA-A2,33, B61, CW3, HLA-DR4,15 , HLA-DRB1*1501,0406, HLA-DQ1,3. Donor D2 is a HLAidentical sibling BMT donor for a CML female patient aged 43 years old. Bone marrow cells were collected from the CML patient during post-BMT relapse, after obtaining informed consent approved by a local ethical committee. Patient's marrow cells showed the 9;22 translocation and were b2a2 negative/b3a2 positive by reverse-transcriptase polymerase chain reaction. Bone marrow mononuclear cells were isolated by density gradient centrifugation (Lymphoprep; Nycomed), then cryopreserved in 10% DMSO at −80°C to be used later as target cells in the cytotoxic assays as described below.
Isolation and culture conditions of DC
Blood DC precursors can be identified by the expression of CD4 and HLA-DR surface antigens and the absence of B cell, T cell, NK cell and monocytic cell specific antigens. [23] [24] [25] Using the MACS blood DC isolation kit (lot No. NE 5325; Miltenyi Biotec, Auburn, CA, USA), blood DC precursors were enriched from PBMC by two-step immunomagnetic separation. In a first MACS separation, blood DC were pre-enriched from PBMC by immunomagnetic depletion of CD3 + T cells, CD 11b
+ monocytic cells and CD16 + NK cells. CD3 + , CD11b + cells were indirectly magnetically labeled using a cocktail of hapten-conjugated primary monoclonal antibodies (mAbs) and an anti-hapten mAb coupled to MACS microbeads. The magnetically labeled cells were depleted by retaining them on a depletion column in the magnetic field of the magnetic cell separator VarioMACS (Miltenyi Biotec). In a second MACS separation, CD4 + blood DC were positively selected from the non-magnetic fraction. The CD4 + blood DC precursors were magnetically labeled using direct CD4 microbeads and subsequently enriched on a positive selection column. The isolated DC precursors were cultured at 3 × 10 5 /ml in CM, supplemented with 10% autologous plasma. 100 ng/ml GM-CSF and 10 ng/ml IL-4 were added on the initial day of DC culture. First and second pulse for DC using bcr-abl (b3a2) peptide were done respectively on day 3 and day 5 of DC culture. One day after the second bcr-abl peptide pulse for DC, 10 ng/ml TNF-␣ was added for maturation of DC. In most experiments, for future application in our clinical trials, DC were generated from peripheral blood adherent cells using a previously established procedure. 12, 15 Briefly, PBMC were separated from whole blood by density gradient centrifugation (Lymphoprep; Nycomed), and a cell density of 2 × 10 6 /ml in CM supplemented with 10% autologous plasma were plated in 100 × 20 mm tissue culture plates (Falcon, Becton Dickinson, NJ, USA). PBMC were incubated for 2 h in a humidified incubator supplemented with 5% CO 2 at 37°C. To generate DC, the adherent cells were cultured in fresh CM supplemented with 10% autologous plasma. 100 ng/ml GM-CSF and 10 ng/ml IL-4 were added on the initial day of DC culture. One day after the second bcr-abl peptide pulse for DC, 10 ng/ml TNF-␣ was added for maturation of both peptidepulsed and non-pulsed DC. Purity of DC fractions was confirmed by assessment of morphology under phase contrast microscopy and by immunophenotyping as described below.
Evaluation of the purity of DC precursors after immunomagnetic isolation
Aliquots of each cell fraction before and after DC isolation were stained with a cocktail of fluorochrome-conjugated mAbs to follow up the purification of blood DC precursors. The cocktail contained mAbs specific for T cells (anti-TCR ␣/␤, Becton Dickinson Immunocytometry systems, Mountain View, CA, USA), B cells (anti-CD19, Becton Dickinson), NK cells (anti-CD56, Becton Dickinson), and monocytes (anti-CD14, Becton Dickinson), coupled to fluorescein isothiocyanate (FITC), and a mAb against HLA-DR (Becton Dickinson) coupled to phycoerythrin (PE). Methods of flow cytometry and data analysis have been done as described previously. 26 Appropriate isotype-matched nonspecific control mAbs were used in all experiments to determine the levels of background staining. Flow cytometry was performed using a FACScan (Becton Dickinson), and 10 000 cells were analyzed per sample.
Phenotypic analysis of cultured DC
Surface adhesion molecules expressed by cultured DC were examined by single-color analysis using direct immunofluorescence and flow cytometry. A panel of mAbs was used to characterize blood adherent cells derived DC cultured for 7 days in the presence of GM-CSF + IL-4, or GM-CSF + IL-4 + TNF-␣. The mAbs used were as follows: PE-conjugated anti-human CD80 (L307.4; Becton Dickinson, San Jose, CA, USA), PE-conjugated anti-human HLA-DR (L234; Becton Dickinson), PE-conjugated anti-human CD83 (IM2218; Immunotech, Marseille, France), PE-conjugated anti-human CD14 (MY4; Coulter, Hialeah, FL, USA), and PE-conjugated antihuman CD1a (T6; Coulter). Appropriate isotype-matched non-specific control mAbs were used to determine the levels of background staining. Flow cytometry and data analysis were performed using a FACScan (Becton Dickinson), and 10 000 cells were analyzed per sample. 26 
Synthetic peptide
Synthetic peptide 12 amino acids in length (GFKQSSKALQRP), spanning the b3a2 junctional region of bcr-abl, was synthesized on the basis of the published amino acid sequences. 16 The peptide was synthesized using solidphase strategy on an automated multiple peptide synthesizer (Abimed AMS 422, Langenfeld, Germany) with the Fmoc procedure, 27 purified by C18 reversed phase high performance liquid chromatography, and characterized by amino acid sequence analysis and mass spectrometry. Peptide was stored at −70°C in an aliquot of 1 ml in a concentration of 10 mg/ml in phosphate-buffered saline (154 mmol/l NaCl, 1.4 mmol/l Na 2 HPO 4 , pH 7.5). Peptide purity was estimated to be 99.71% by high performance liquid chromatography.
Culture of peptide pulsed macrophages
PBMC at a density of 2 × 10 6 cells/ml were cultured in CM containing 10% autologous plasma. The PBMC were plated in 100 × 20 mm tissue culture plates (Falcon), and incubated for 2 h in a humidified incubator supplemented with 5% CO 2 at 37°C. The non-adherent cells were collected by moderately vigorous aspiration and used as effector cells in cytotoxic assays. Macrophages were recovered by culturing the adherent cells in fresh CM supplemented with 10% autologous plasma, and 50 ng/ml M-CSF was added on the initial day of culture. On the third day of macrophage culture b3a2 peptide was added at a final concentration of 50 g/ml for single stimulation immediately after replenishment with fresh CM containing 10% autologous plasma and 50 ng/ml M-CSF. After a total of 6 days of macrophage culture, peptide-pulsed and non-pulsed macrophages were harvested using a cell scraper (Costar, Cambridge, MA, USA), and used as target cells in peptide-specific cytotoxicity as described below.
Generation of peptide-specific CTL
Non-adherent cells were stimulated in vitro with 12 mer b3a2 junction peptide-pulsed autologous DC. Briefly, 1 × 10 6 /ml freshly isolated non-adherent peripheral blood cells were stimulated with 1 × 10 5 /ml autologous, 30 Gy irradiated, peptide-pulsed DC, in CM containing 10% autologous plasma. For peptide-pulsing of autologous DC, the b3a2 peptide was added at a final concentration of 50 g/ml at the first stimulation and 15 g/ml at the second stimulation, similar to the protocol of Bocchia et al. 28 After a total of 6 days of co-culturing peptide-pulsed or non-pulsed DC with non-adherent cells, cells in co-culture plates were harvested and phenotypically characterized, then used as effector cells in peptide-specific cytotoxicity as described below.
Cytokine assays
The production of GM-CSF and TNF-␣ by b3a2 pulsed DCprimed PBL was analyzed as reported previously. 29, 30 Commercial enzyme-linked immunosorbent assay (ELISA) kits were used for assessing concentrations of cytokines in culture supernatants from DC-PBL co-culture plates. Cell-free culture supernatants were harvested after a total of 6 days of co-culturing b3a2 peptide-pulsed or non-pulsed DC with non-adherent cells (at 37°C in a 5% CO 2 incubator) and used for cytokine assays as described below.
Tumor necrosis factor alpha: TNF-␣ was quantified using the Quantikine-HS TNF-␣ immunoassay kit. This assay is a solid phase ELISA that specifically measures TNF-␣ (sensitivity of 0.5 pg/ml). The Quantikine-HS TNF-␣ immunoassay contains E. coli-derived recombinant human TNF-␣ and antibodies raised against this E. coli-derived protein. The Quantikine-HS TNF-␣ assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for TNF-␣ has been coated on to the microtiter plate provided in the kit. Standards and samples are pipetted into the wells and any TNF-␣ present is bound to the immobilized antibody. After washing away any unbound proteins, an enzyme-linked polyclonal antibody specific for TNF-␣ is added to the wells to sandwich the TNF-␣ immobilized during the first incubation. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells. After an incubation period, an amplifier solution is added to the wells and color develops in proportion to the amount of TNF-␣ bound in the initial step. The color development is stopped and the intensity of the color is measured in an ELISA plate reader. The Quantikine-HS TNF-␣ immunoassay kit was purchased from R&D Systems Minneapolis, MN, USA.
Granulocyte-macrophage colony-stimulating factor:
GM-CSF was assayed using the Biotrak human GM-CSF system from Amersham (Biotrak, code 2151; Amersham, Little Chalfont, UK). The assay system is based on a solid phase ELISA, which uses a highly specific mAb for GM-CSF bound to the wells of a microtiter plate, together with a monospecific antibody to GM-CSF conjugated to horseradish peroxidase. The sensitivity of Biotrak GM-CSF immunoassay kit is 2.8 pg/ml.
Phenotypic characterization of b3a2 peptide-pulsed DC-primed or non-primed PBL
FITC-or PE-conjugated mAbs against CD3, CD4, CD8, CD19, CD56, CD57, CD16, CD11b, CD25, CD20, CD5, CD2, TCR ␣␤, TCR ␥␦, CD22, CD122, and HLA-DR and fluorochromelabeled isotype controls were purchased commercially (Becton Dickinson). The b3a2 peptide-pulsed DC-primed or non-primed PBL of donor D1 were incubated with various combinations of mAbs, washed with phosphate-buffered saline and analyzed using a FACScan flow cytometer and the LYSIS software (Becton Dickinson). Methods and data analysis of flow cytometry have been done as described previously, 26 and 10 000 cells were analyzed per sample.
CTL cytotoxicity assay
The specific cytotoxicity of non-adherent cells was measured in a standard 51 Cr release assay. 31 In brief, bcr-abl peptidepulsed and non-pulsed autologous macrophages, or thawed CML marrow cells were labeled with 100 Ci/10 6 cells of 51 Cr (New England Nuclear, Boston, MA, USA) for 2 h, and then washed three times with CM. Target cells (1 × 10 4 /well) were mixed with effector cells at various effector-to-target (E:T) ratios in triplicate in 96-well round-bottom plates (Falcon; Becton Dickinson). The total volume per well was adjusted to 0.2 ml with CM and lysis of target cells was measured 4 h later by counting 0.1 ml of culture supernatant using the auto-well gamma system Aloka ARC-300 (Aloka, Tokyo, Japan). The specific cytotoxicity was expressed as the percentage of 
Statistical analysis
The statistical relevance of differences in % cytotoxicity was evaluated with two-way ANOVA test, applying GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Differences were considered as highly significant for P Ͻ 0.001, and as not significant for P Ͼ 0.05.
Results
Evaluation of the purity of DC precursors after immunomagnetic isolation
To evaluate the purity of DC precursors, a flow cytometry analysis was performed on pre-and post-DC precursor isolation aliquots. The % of DC within the pre- (Figure 1a ) and post- (Figure 1b ) isolation aliquots were Ͻ0.5% and Ͼ95%, respectively.
Phenotypic analysis of cultured DC
We examined the surface molecules expressed on DC cultured from peripheral blood adherent cells for 7 days in the presence of GM-CSF + IL-4, or GM-CSF + IL-4 + TNF-␣. As shown in Figure 2 , adding TNF-␣ to GM-CSF + IL-4, resulted in increased intensity of CD1a 
Induction of CTL against bcr-abl peptide-pulsed autologous macrophages
DC pulsed with 12 mer b3a2 junction peptide were tested for the capability of stimulating non-adherent cells of normal donor to lyse b3a2 peptide-pulsed autologous target cells. As indicated in Figure 3 , in which DC were generated from peripheral blood adherent cells of donor D1, the b3a2 peptidepulsed DC-primed PBL showed significantly high cytotoxic activity against b3a2 peptide-pulsed autologous macrophages. At E:T ratios of 60:1, 30:1, and 15:1, the cytotoxic activities of b3a2 peptide-pulsed DC-primed PBL against b3a2 peptidepulsed autologous macrophages were 86%, 71%, and 27%, Figure 1 The purity of the isolated blood DC precursors was evaluated by two color flow cytometry analysis as described in Materials and methods. The % of DC within the pre-(a) and the post-(b) isolation aliquots is indicated in the Figure. respectively. At the same E:T ratios as above, the cytotoxic activities of b3a2 peptide non-pulsed DC-primed PBL against b3a2 peptide-pulsed autologous macrophages were demonstrated to be less than 20% (19%, 17%, and 15%, respectively). In addition, Figure 3 indicates that the cytotoxic activities of both b3a2 peptide-pulsed DC-primed and nonprimed PBL against b3a2 peptide non-pulsed autologous macrophages were nearly zero. To confirm the above results, similar experiments were done using DC generated from purified DC precursors employing DC isolation kit (Figure 4) . Figure 4 illustrates that at E:T ratios of 30:1, 15:1, and 7.5:1, the b3a2 peptide-pulsed DC-primed PBL displayed significant cytotoxic activity against b3a2 peptide-pulsed autologous macrophages (53%, 29%, and 22%, respectively). In Figure  4 , at the same E:T ratios mentioned, the cytotoxic activities of b3a2 peptide non-pulsed DC-primed PBL against b3a2 peptide-pulsed autologous macrophages were demonstrated to be 36%, 15%, and 14%, respectively. Besides, the cytotoxic activities of both b3a2 peptide-pulsed DC-primed and nonprimed PBL against b3a2 peptide non-pulsed autologous macrophages were nearly zero.
Induction of CTL against b3a2 positive marrow cells derived from CML patient
DC pulsed with b3a2 peptide were examined for the capability of stimulating non-adherent cells of a normal donor to lyse b3a2 positive marrow cells derived from HLA-identical sibling CML patient. As indicated in Figure 5 , in which DC were generated from cultured peripheral blood adherent cells of donor D2, the b3a2 peptide-pulsed DC-primed PBL showed significantly higher cytotoxic activity compared with peptide non-pulsed DC-primed PBL against b3a2 positive marrow cells of HLA-identical sibling CML patient (P Ͻ 0.001). At E:T ratios of 16:1, 8:1, and 4:1, the cytotoxic activities of b3a2 peptide-pulsed DC-primed PBL against CML cells were 68%, 16%, and 6%, respectively. At the same E:T ratios as above, the cytotoxic activities of peptide non-pulsed DC-primed PBL against CML cells were demonstrated to be 8%, and nearly zero, respectively.
HLA-restriction of the b3a2 peptide-specific CTL response
In Figure 6 (a and b), DC were generated from cultured peripheral blood adherent cells of donors D3 and D4, respectively. As demonstrated for both donors, the b3a2 peptidepulsed DC-primed and non-primed PBL were almost null in their cytotoxic activity against b3a2 peptide-pulsed autologous macrophages.
Identification of cytokines in supernatants from b3a2 peptide-pulsed or non-pulsed DC-PBL co-culture
The effect of b3a2 peptide-pulsed or non-pulsed DC on the production of cytokines by T cells was studied for donor D1 (Table 1) . Peptide-pulsed DC-primed T cells were significantly superior in their production of GM-CSF in comparison with peptide non-pulsed DC-primed T cells (2774.8 pg/ml eliminate, and 1456.8 pg/ml, respectively). In addition, antileukemic cytokine that is TNF-␣ produced by T cells was significantly superior in peptide-pulsed DC-primed T cells compared with
Figure 3
Cytotoxic activity of normal donor (D1) PBL primed with b3a2 peptide-pulsed or non-pulsed autologous DC against autologous macrophages pulsed or non-pulsed with b3a2-peptide. In this experiment, DC were generated from peripheral blood adherent cells as described in Materials and methods. Cytotoxicity was assessed in a 4-h assay. Results are reported as percent specific 51 Cr release from 10 4 target cells at varying effector-to-target (E:T) ratios. The E:T ratios are 60:1, 30:1, and 15:1. The standard error of the mean (s.e.m.) of triplicate counts per one experimental setting was always less than 10% of the mean. The specific cytotoxic activity of b3a2 peptidepulsed DC-primed CTL was significantly high in comparison with b3a2 peptide non-primed CTL (P Ͻ 0.001). (P.E, peptide-pulsed DCprimed effector; P.T, peptide-pulsed target; nonP.E, peptide nonpulsed DC-primed effector; nonP.T, peptide non-pulsed target).
Figure 4
Cytotoxic activity of normal donor (D1) PBL primed with b3a2 peptide-pulsed or non-pulsed autologous DC against autologous macrophages pulsed or non-pulsed with b3a2-peptide. In this experiment, DC were generated from purified DC precursors employing DC isolation kit as described in Materials and methods. Cytotoxicity was assessed in a 4-h assay. Results are reported as percent specific 51 Cr release from 10 4 target cells at varying E:T ratios. The E:T ratios are 30:1, 15:1, and 7.5:1. The s.e.m. of triplicate counts per one experimental setting was always less than 9% of the mean. The specific cytotoxic activity of b3a2 peptide-pulsed DC-primed CTL was significantly high in comparison with b3a2 peptide non-primed CTL (P Ͻ 0.001). (Abbreviations as in Figure 3 ).
Figure 5
Cytotoxic activity of normal donor (D2) PBL primed with b3a2 peptide-pulsed or non-pulsed autologous DC against b3a2 positive marrow cells derived from HLA-identical sibling CML patient who relapsed post-allogeneic BMT. In this experiment, DC were generated from peripheral blood adherent cells as described in Materials and methods. Cytotoxicity was assessed in a 4-h assay. Results are reported as percent specific 51 Cr release from 10 4 target cells at varying E:T ratios. The E:T ratios are 16:1, 8:1, and 4:1. The s.e.m. of triplicate counts per one experimental setting was always less than 10% of the mean. The specific cytotoxic activity of b3a2 peptidepulsed DC-primed CTL was significantly higher than peptide nonprimed CTL (P Ͻ 0.001). (Abbreviations as in Figure 3 ).
peptide non-pulsed DC-primed T cells (215 pg/ml eliminate, and 149 pg/ml, respectively). Table 2 shows the phenotypic analysis of b3a2 peptide-pulsed DC-primed or non-primed PBL from donor D1, that were involved as effector cells in the cytotoxicity assays. Notably, the percentage of CD4 + effector cell populations increased after the b3a2 peptide-pulsed DC-priming (58.2% vs 45.8%). Although the percentage of CD8 + cells did not change significantly after priming with b3a2 peptide-pulsed DC (20.9% vs 19.4%), CD8
Phenotypic characterization of b3a2 peptide-pulsed DC-primed PBL
− cytotoxic T cells were higher among the effector cell populations of b3a2 peptide-pulsed DCprimed PBL, compared with peptide non-primed PBL (18.8% and 14.1%, respectively).
Discussion
In our present study we have investigated the potential of b3a2 peptide-pulsed DC to activate CTL for DLT in relapsed CML after HLA-matched sibling BMT. DC grown from normal peripheral blood adherent cells, or purified DC precursors, were cultured in the presence of GM-CSF and IL-4 then were induced to become mature and functional DC by the addition of TNF-␣. The b3a2 peptide pulsed-DC could elicit a potent CTL response in vitro against b3a2 peptide-pulsed autologous macrophages, or b3a2 positive marrow cells derived from HLA-identical sibling CML patient. Data of donors D1 and D2 showed that the peptide-pulsed DC-primed PBL (both CD8 + and CD4 + T cells) displayed significantly higher cytotoxic activity in comparison with peptide non-pulsed DC-primed PBL, against peptide-pulsed autologous macrophages, or marrow cells derived from HLA-identical sibling CML patient (P Ͻ 0.001). Besides, b3a2 peptide-pulsed DC-primed T cells (a and b). Cytotoxic activity of normal donor (D3 and D4, respectively) PBL primed with b3a2 peptide-pulsed or non-pulsed autologous DC against autologous macrophages pulsed or non-pulsed with b3a2 peptide. For both donors, DC were generated from peripheral blood adherent cells. Cytotoxicity was assessed in a 4-h assay. Results are reported as percent specific 51 Cr release from 10 4 target cells at varying E:T ratios. The s.e.m. of triplicate counts per one experimental setting was always less than 8% of the mean. For both donors (D3 and D4), the specific cytotoxic activity of b3a2 peptidepulsed DC-primed CTL was almost null and did not differ from that of b3a2 peptide non-primed CTL (P Ͼ 0.05). (Abbreviations as in Figure 3) .
Table 1
Identification of cytokines in DC/PBL co-culture supernatants Cytokine b3a2 non-stimulated b3a2-stimulated PBL PBL GM-CSF 1456.8 pg/ml 2774.8 pg/ml TNF-␣ 149 pg/ml 215 pg/ml Identification of cytokines in supernatants from b3a2-peptide pulsed or non-pulsed DC/PBL co-culture. 1 × 10 6 /ml fresh PBL from donor D1 were co-cultured with 1 × 10 5 /ml autologous, 30 Gy irradiated, peptide-pulsed or non-pulsed DC, in CM containing 10% autologous plasma. After a total of 6 days of co-culturing peptidepulsed or non-pulsed DC with PBL, cell-free supernatants from co-culture plates were harvested, and cytokine assays were performed.
were significantly superior to peptide non-pulsed DC-primed T cells in the production of GM-CSF, and antileukemic cytokine, that is TNF-␣. In the experiments employing DC derived from adherent cells of donor D1, the average cytotoxic activity of peptide-pulsed DC-primed PBL against autologous peptidepulsed target cells at E:T ratio of 60:1 was 86%. Although we do not know the exact cause, our present study demonstrated that for donor D1, at a 30:1 E:T ratio the specific cytotoxicity of CTL generated on adherent cell-derived DC was greater than that of CTL generated on DC gained by immunomagnetic separation (71% vs 53%). As mentioned above, DC generated from peripheral blood adherent cells had the equivalent or more activity to prime T lymphocytes, compared with DC gained by immunomagnetic separation. Besides, the adherent cell-derived DC are easier to obtain and clinically more applicable. Therefore, we used the peripheral blood adherent cells as a source of DC in our following studies. Both b3a2 peptidepulsed DC-primed and non-primed PBL gave no cytotoxic response against the peptide non-pulsed autologous target cells in our studies employing culture system supplemented with autologous plasma. Similar findings using CD8 + T cell clones/lines as effector cells have been reported recently. 21 However, here we used normal donor PBL (including both CD8
+ and CD4 + populations) as effector cells in our designed preclinical trials, and tested their in vitro ability to generate sufficient peptide-specific cytotoxic responses against autologous peptide-pulsed target cells, or b3a2 positive marrow cells derived from HLA-identical sibling CML patient. In a clinical setting as DLT for relapsed CML, our present study could imply ex vivo-generation of donor peptide-specific and efficient CTL for transfusion in marrow grafted patients in relapse. We showed that DC isolated from normal peripheral blood adherent cells of donor D2 and pulsed with b3a2-peptide, have generated specific and efficient in vitro CTL responses against b3a2 positive marrow cells derived from HLA-identical sibling CML patient. At E:T ratios of 16:1, 8:1, and 4:1, the b3a2 peptide-pulsed DC-primed PBL of donor D2 showed significantly high cytotoxic activity in comparison with peptide non-pulsed DC-primed PBL against b3a2 positive marrow cells derived from HLA-identical sibling CML patient (P Ͻ 0.001). We think that the cytotoxic activity induced by peptide non-pulsed DC-primed PBL of donor D2 against leukemic cells derived from HLA-identical sibling CML patient, might represent the in vitro model system of the antileukemic effect of non-sensitized DLT for this donor-patient pair. Our present data showed that the b3a2 peptide-pulsed DC-primed PBL are significantly superior to peptide non-pulsed DCprimed PBL in both peptide-specific cytotoxic activity and production of cytokines. These findings suggested that such methodology might be feasible to generate efficient cells for antileukemic immunotherapy in clinical DLT settings for relapsed CML patients after BMT. We think that the cytotoxic activity induced by b3a2-peptide non-primed PBL against b3a2 peptide-pulsed autologous target cells, that was shown especially in the study using immunomagnetically isolated DC, is probably due to macrophages which were cultured as target cells and possess the function of APC. Peptide-pulsed macrophages may have presented b3a2-peptide to autologous PBL and induced the peptide non-primed PBL to display mild cytotoxic activity against peptide-pulsed target cells in vitro. Our present results indicating that b3a2-peptide specific cytotoxicity of peptide-pulsed DC-primed PBL are significantly high, suggest that in vitro-generated DC can be effectively used as APC for intensification of specific antileukemic effects of DLT. Because DC induce antigen-specific T cell primary Phenotypic characterization of b3a2 peptide-pulsed DC-primed or non-primed PBL. In this experiment, b3a2 peptide-pulsed DC-primed or non-primed PBL were generated from peripheral blood of donor D1 as described in Materials and methods. The b3a2 peptide-pulsed DC-primed or non-primed PBL were stained with FITC-or PE-conjugated mAbs and analyzed by flow cytometry.
responses in vitro, 7 and in vivo, [32] [33] [34] they are important 'nature's adjuvant' for the immune system. 7 Nevertheless, in vivo DC precursors have scattered locations and are found in a very low frequency of approximately 0.1% of leukocytes in the peripheral blood. Besides, the in vivo mature and functional DC are thought to be very scanty. 35, 36 In our designed preclinical trials, we demonstrated that CD83 + , CD1a , functional DC were derived from normal peripheral blood adherent cells in the presence of GM-CSF + IL-4 + TNF-␣. These peptide-pulsed mature DC stimulated vigorous peptide specific cytotoxic activity against peptide-pulsed autologous target cells, or marrow cells derived from a HLA-identical sibling CML patient who relapsed post-allogeneic BMT. Furthermore, our present preclinical studies proposed that active cytotoxic response specific to the bcr-abl peptide is not likely to be harmful, since this peptide is unique to the leukemia cells, and because peptide-pulsed DC-primed PBL gave no cytotoxic response against the peptide non-pulsed autologous target cells in our culture system supplemented with autologous plasma. From the theoretical point of view, because bcr-abl fusion protein is involved in the leukemogenic events in CML, antigen-negative clonogenic cells are likely to be rare. Thus, the chance of bcr-abl positive CML cells to escape from antileukemic effects of DLT is not probable. 37 In our study, the HLA types of the healthy donors D1 and D2 are HLA-A2,24, B48,70, HLA-DR4, HLA-DRB1* 0403,0405, HLA-DQ3,4; and HLA-A11,13, B51,41, CW6, HLA-DR4,4, respectively. DC of donors D1 and D2 have presented the b3a2-peptide effectively to responding autologous PBL. However, HLA-restriction of the b3a2-specific response has to be considered as indicated by the absence of significant cytotoxic activity induced by b3a2 peptide-pulsed DC-primed PBL from donors D3 and D4. There is now a growing list of HLA alleles that have been shown to present bcr-abl peptides to in vitro-generated T-lymphocyte lines. These include HLA-DR1, 16 -4, 19 -3, -11, 20 -15, 18 HLA-A3, 22 -A11 and B8. 37 In conclusion, our present study may provide an evidence for the possible use of DC derived from normal blood adherent cells as APC for the induction of peptide-DC primed CTL. These normal donor peptide-specific CTL might be applied clinically in DLT for relapsed CML patients after HLA-matched sibling BMT. Development of efficient peptide-DC based immunotherapy for CML, however, will require carefully planned human trials.
